Log In
BCIQ
Print this Print this
 

DIG-KT (PMC-001)

  Manage Alerts
Collapse Summary General Information
Company PharmAbcine Inc.
DescriptionBispecific antibody against vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1; VEGFR-2) and tyrosine kinase receptor 2 (Tie2)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) ; Tyrosine kinase receptor 2 (Tie2)
Mechanism of ActionTyrosine kinase receptor 2 (Tie2) inhibitor; Bispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner3SBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/15/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today